| | 700874-71-1 Basic information More.. |
| Product Name: | LY2109761 | | Synonyms: | LY2109761/LY-2109761;LY2109761;Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[2-(4-Morpholinyl)ethoxy]-;4-[5,6-Dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[2-(4-morpholinyl)ethoxy]quinoline;LY210976;4-[2-[4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]oxyethyl]Morpholine;N-CYCLOPENTYL-WEI -ALANINE;N-CYCLOPENTYL-Β-ALANINE | | CAS: | 700874-71-1 | | MF: | C26H27N5O2 | | MW: | 441.52 | | EINECS: | | | Mol File: | 700874-71-1.mol |  |
Use
LY2109761 treatment induces a dose-dependent low-anchorage growth inhibition of L3.6pl/GLT cells, leading to ~33% or 73% inhibition at 2 μM and 20 μM, respectively, which can be strongly enhanced when combined with gemcitabine in combination index value of 0.36581. Blocking TβRI/II kinase activity with LY2109761 (5 μM) completely suppresses both the basal and TGF-β1-stimulated migration and invasion of L3.6pl/GLT cells, significantly enhances the detachment-induced apoptosis by 26% at 8 hours treatment, and completely suppresses TGF-β–induced Smad2 phosphorylation. LY2109761 treatment at 1 nM is sufficient to significantly block the migration and invasion but not adhesion of hepatocellular carcinoma cells by increasing E-cadherin expression. LY2109761 pretreatment enhances radiosensitivity of glioblastoma cells via TGF-β signaling blockage. LY2109761 (10 μM) reduces the self-renewal and proliferation of GBM-derived cancer stem–like cells (CSLC), which can be significantly enhanced when combined with radiation.
- LY2109761
-
- US $39.00-113.00 / mg
- 2026-04-23
- CAS:700874-71-1
- Min. Order:
- Purity: 99.99%
- Supply Ability: 10g
- LY2109761
-
- US $7.00 / KG
- 2020-01-14
- CAS:700874-71-1
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 1000kg
|
|
700874-71-1
Recommend Suppliers |
|